Biotech firm Amgen lays out plans for its Humira’s biosimilar
Biotechnology firm, Amgen, is planning to make its mark first U.S. biosimilar to AbbVie’s megablockbuster Humira. During the 2022 Biotechnology Innovation Organization (BIO) Convention, Amgen presented a preview of its annual trends in…